+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)


Antidepressant Market - Growth, Trends, and Forecasts (2020 - 2025)

  • ID: 4756838
  • Report
  • May 2020
  • Region: Global
  • 112 pages
  • Mordor Intelligence
1 of 4

Enquire about COVID-19 updates for this product.

Enquire Now


  • Allergan PLC
  • AstraZeneca
  • Eli Lilly and Company
  • GlaxoSmithKline PLC
  • H. Lundbeck AS
  • Johnson & Johnson
  • MORE
The global antidepressant market is driven by the rising cases of depression, increasing awareness about depression, and the emergence of novel biologics.

According to the World Health Organization 2017, Depression is a more common disorder and affects about 297 million worldwide is a major contributor to the overall global burden of disease. Depression mainly occurs due to the factors, such as social isolation and stressful work environment has contributed the most toward increasing the number of people suffering from depression. The number of people falling prey to depression and related disorders is expected to continue to increase, as a result of improper eating habits, stressful work schedule, increasing isolation from family and loved ones due to technology, and the inability to adapt to the rapid pace, at which, the world is moving forward.

In countries, such as the United Kingdom and the United States, which are characterized by their fast-paced economies, the percentage of 'affected population' in every age group is quite high. According to the Office for National Statistics 2017, 1 in every 4 people in the United Kingdom affected by depression. Thus, the rising cases of depression across the world are expected to drive the overall growth of the market studied over the forecast period.

However, the availability of non-drug treatments and side effects associated with the anti-depressants are projected to hinder the market growth over forecast period.

Key Market Trends

Major Depressive Disorder Segment by Depressive Disorder is Projected to Account for the Significant Share

The major depressive disorder possible causes comprise of the combination of biological, psychological, and social sources of distress. The major risk factors include family history, significant life changes, certain medications, chronic health problems, and substance abuse. As per the data published by the National Institute of Mental Health, In 2017, an estimated 17.3 million adults in the United States had at least one major depressive episode. This number represented 7.1% of all US adults and is majorly prevalent in women as compared to men.

Most commonly, selective serotonin reuptake inhibitors (SSRI) are used in the treatment of major depression, while there are some therapies available to normalize brain changes associated with depression.

In October 2018, Lundbeck has launched Brintellix tablets, which are used for the treatment of Major Depressive Disorder in India. Similarly, in April 2019, Lupin has launched antidepressant Fluoxetine tablets in the American market. The tablets are indicated for the treatment of the major depressive disorder, obsessive-compulsive disorder.

Thus, owing to the rising number of the patient pool and recemnt product launches the market is expected to witness high growth in United States over the forecast period.

North America Projected to Have Significant Share in the Global Market

The increasing cases of depression are one of the major factors that are expected to drive the overall growth of the US antidepressant market over the forecast period. Moreover, there is a rise in the geriatric population in the United States, which is expected to create more opportunities for market players in the region. Women are twice as likely to be affected by generalized anxiety disorder (GAD) when compared to men. Six million adults or 2.7% of the US population suffer from panic disorders, and around 2.2 million or 1.0% of the US population suffer from obsessive-compulsive disorder (OCD), which is found to be equally common among men and women.

The two major factors leading to the rise in the consumption of antidepressants are the course of the treatment lasting longer than it used to be, and the antidepressants that are currently being prescribed are not only for severe depression, but also for mild depression, anxiety, social phobia, and more. The increasing prevalence of disorders and increasing rate of consumption of antidepressants are expected to drive the market studied during the forecast period.

Competitive Landscape

The market studied comprises of a combination of multinational and domestic players. The entry barriers are comparatively less, and most of the drugs are available over the counter. The companies are trying to expand their geographical presence by partnerships or acquisitions. In March 2019, The U.S. Food and Drug Administration has approved Spravato nasal spray, in conjunction with an oral antidepressant, for the treatment of depression in adults who have tried other antidepressant medicines but have not benefited from them (treatment-resistant depression).

Some of the key players in the market are Allergan PLC, AstraZeneca, Eli Lilly and Company, GlaxoSmithKline PLC, H. Lundbeck AS, Johnson & Johnson, and Pfizer Inc.

Reasons to Purchase this report:
  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

This report will be delivered within 2 business days.
Note: Product cover images may vary from those shown
2 of 4


  • Allergan PLC
  • AstraZeneca
  • Eli Lilly and Company
  • GlaxoSmithKline PLC
  • H. Lundbeck AS
  • Johnson & Johnson
  • MORE
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study



4.1 Market Overview
4.2 Market Drivers
4.2.1 Rising Cases of Depression
4.2.2 Increasing Awareness about Depression
4.2.3 Emergence of Novel Biologics
4.3 Market Restraints
4.3.1 Preference of Non-pharmacological Therapies over Pharmacological Therapies
4.3.2 Side-effects and Patent Expiry of Antidepressant Drugs
4.4 Porter's Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry

5.1 By Product
5.1.1 Selective Serotonin Reuptake Inhibitor (SSRI)
5.1.2 Serotonin-norepinephrine Reuptake Inhibitor (SNRI)
5.1.3 Tricyclic Antidepressant (TCA)
5.1.4 Monoamine Oxidase Inhibitor (MAOI)
5.1.5 Other Products
5.2 By Depressive Disorder
5.2.1 Major Depressive Disorder
5.2.2 Obsessive-compulsive Disorder (OCD)
5.2.3 Generalized Anxiety Disorder (GAD)
5.2.4 Panic Disorder (PD)
5.2.5 Other Depressive Disorders
5.3 Geography
5.3.1 North America United States Canada Mexico
5.3.2 Europe Germany United Kingdom France Italy Spain Rest of Europe
5.3.3 Asia-Pacific China Japan India Australia South Korea Rest of Asia-Pacific
5.3.4 Middle East & Africa GCC South Africa Rest of Middle East & Africa
5.3.5 South America Brazil Argentina Rest of South America

6.1 Company Profiles
6.1.1 Allergan PLC
6.1.2 AstraZeneca
6.1.3 Eli Lilly and Company
6.1.4 GlaxoSmithKline PLC
6.1.5 H. Lundbeck AS
6.1.6 Johnson & Johnson
6.1.7 Merck & Co. Inc.
6.1.8 Pfizer Inc.
6.1.9 Sanofi
6.1.10 Sun Pharmaceuticals Pvt Ltd

Note: Product cover images may vary from those shown
3 of 4


4 of 4
  • Allergan PLC
  • AstraZeneca
  • Eli Lilly and Company
  • GlaxoSmithKline PLC
  • H. Lundbeck AS
  • Johnson & Johnson
  • Merck & Co. Inc.
  • Pfizer Inc.
  • Sanofi
  • Sun Pharmaceuticals Pvt Ltd
Note: Product cover images may vary from those shown